Keeping Track: Lilly's Olaratumab, Cempra's Solithromycin, AAA's Lutathera Complete Submissions; End Of The Road For Rociletinib

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

More from United States

More from North America